Larimar: Q3 Earnings Snapshot
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
Larimar Therapeutics Q3 EPS $(0.29) Beats $(0.35) Estimate
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics Completes Rolling BLA Submission To FDA Seeking Accelerated Approval Of Nomlabofusp For Treatment Of Patients With Friedreich’s Ataxia
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia - Slideshow
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.